Yahoo Finance GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
Tuesday, GSK plc (NYSE:GSK) released headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterized by blood eosinophil count.
Earlier this year, GSK acquired Aiolos Bio Inc., a privately held asthma drug maker, for $1 billion.
Both SWIFT-1 and SWIFT-2 met their primary endpoints of a reduction in the annualized rate of clinically significant exacerbations (asthma attacks) over 52 weeks.
Across both trials, the overall incidence and severity of treatment-emergent adverse events were similar in patients treated with either depemokimab or placebo. The company said further analysis of data is ongoing.
Depemokimab is the first ultra-long-acting biologic to be evaluated in phase 3 trials with a binding affinity and high potency for interleukin-5 (IL-5), enabling six-month dosing intervals for patients with severe asthma. IL-5 is a key cytokine (protein) in type 2 inflammation.
This inflammation, typically identified by elevated blood eosinophil count, is the underlying pathology responsible for more than 80% of people with severe asthma and can lead to unpredictable exacerbations.
Kaivan Khavandi, SVP, Global Head of Respiratory/Immunology R&D, said: “These results add to the established body of evidence that targeted inhibition of IL-5 plays a key role in reducing type 2 inflammation that drives severe asthma exacerbations.”
“Depemokimab could offer the possibility of sustained inhibition of this pathway with a dosing schedule of just two injections per year. This is important as research shows that 73% of physicians believe longer dosing intervals would be beneficial to patients who are often juggling multiple therapies.”
Price Action: GSK shares were down 0.74% at $44.26 during the premarket session at the last check on Tuesday.
Photo via Wikimedia Commons
"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!
Get the latest stock analysis from Benzinga?
This article GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
